WO2001089530A3 - Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator - Google Patents

Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator Download PDF

Info

Publication number
WO2001089530A3
WO2001089530A3 PCT/US2001/011768 US0111768W WO0189530A3 WO 2001089530 A3 WO2001089530 A3 WO 2001089530A3 US 0111768 W US0111768 W US 0111768W WO 0189530 A3 WO0189530 A3 WO 0189530A3
Authority
WO
WIPO (PCT)
Prior art keywords
antidepressant
depression
treatment
ampa receptor
combination therapy
Prior art date
Application number
PCT/US2001/011768
Other languages
French (fr)
Other versions
WO2001089530A2 (en
Inventor
Phil Skolnick
Original Assignee
Lilly Co Eli
Phil Skolnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Phil Skolnick filed Critical Lilly Co Eli
Priority to CA002410531A priority Critical patent/CA2410531A1/en
Priority to AU2001261022A priority patent/AU2001261022A1/en
Priority to JP2001585774A priority patent/JP2004509843A/en
Priority to EP01934874A priority patent/EP1292311A2/en
Publication of WO2001089530A2 publication Critical patent/WO2001089530A2/en
Publication of WO2001089530A3 publication Critical patent/WO2001089530A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method for treating depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.
PCT/US2001/011768 2000-05-24 2001-05-11 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator WO2001089530A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002410531A CA2410531A1 (en) 2000-05-24 2001-05-11 Combination therapy for treatment of depression
AU2001261022A AU2001261022A1 (en) 2000-05-24 2001-05-11 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
JP2001585774A JP2004509843A (en) 2000-05-24 2001-05-11 Combination therapy for the treatment of depression
EP01934874A EP1292311A2 (en) 2000-05-24 2001-05-11 Combination therapy for the treatment of depression comprising an antidepressant and an ampa receptor potentiator

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20682500P 2000-05-24 2000-05-24
US60/206,825 2000-05-24

Publications (2)

Publication Number Publication Date
WO2001089530A2 WO2001089530A2 (en) 2001-11-29
WO2001089530A3 true WO2001089530A3 (en) 2002-09-12

Family

ID=22768136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011768 WO2001089530A2 (en) 2000-05-24 2001-05-11 Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator

Country Status (5)

Country Link
EP (1) EP1292311A2 (en)
JP (1) JP2004509843A (en)
AU (1) AU2001261022A1 (en)
CA (1) CA2410531A1 (en)
WO (1) WO2001089530A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438036A2 (en) * 2001-10-12 2004-07-21 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961060A (en) * 1973-05-17 1976-06-01 Astra Lakemedal Aktiebolag Method and compositions for the treatment of neurological disorders
EP0003827A1 (en) * 1978-02-22 1979-09-05 E.I. Du Pont De Nemours And Company Antidepressant combination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961060A (en) * 1973-05-17 1976-06-01 Astra Lakemedal Aktiebolag Method and compositions for the treatment of neurological disorders
EP0003827A1 (en) * 1978-02-22 1979-09-05 E.I. Du Pont De Nemours And Company Antidepressant combination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E.AGUILAR E.A.: "5-HT1 and 5-HT2 receptor agonists blunt (+_)-alpha-amino-3 hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-stimulated GH secretion in prepubertal male rats.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 144, no. 5, 2001, pages 535 - 541, XP008004587 *
G.SCOTT E.A.: "The effects of BTS 54505, a metabolie of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 111, no. 1, 1994, pages 97 - 102, XP000904782 *
J.BERNARD E.A.: "Modulation of the AMPA receptor by phospholipase A2: effect of the antidepressant trimipramine", PSYCHIATRY RESEARCH, vol. 51, no. 2, 1994, pages 107 - 114, XP008004577 *

Also Published As

Publication number Publication date
EP1292311A2 (en) 2003-03-19
AU2001261022A1 (en) 2001-12-03
CA2410531A1 (en) 2001-11-29
JP2004509843A (en) 2004-04-02
WO2001089530A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
WO2004056305A3 (en) Administration of capsaicinoids
PT1333887E (en) METHOD OF TREATMENT OF MUSCULAR DISORDERS
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
WO2003034995A3 (en) Integrin targeting compounds
AU2003224742A1 (en) Method of administering buprenorphine to treat depression
EP2279742A3 (en) Combinations for the treatment of immunoinflammatory disorders
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2004098527A3 (en) Methods of treating neuralgic pain
GB0020504D0 (en) Therapeutic method
BR0307022A (en) Method of treating a patient who needs analgesia
SE9902597D0 (en) New use
WO2001089530A3 (en) Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
AU3885799A (en) Antidepressant therapy
WO2001054678A3 (en) Combination therapy for cancer
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO2002089848A3 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
WO2001089557A3 (en) Methods for preventing strokes by inducing tolerance to e-selectin
WO2001089510A3 (en) Use of an ampa receptor potentiator for the treatment of obesity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10258558

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001934874

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2410531

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001934874

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001934874

Country of ref document: EP